Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Pluristem Therapeutc (PSTI)

Pluristem Therapeutc (PSTI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Lead Physicians in Pluristem's Pivotal Study in Critical Limb Ischemia Publish Peer-Reviewed Paper

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, announced the publication of a peer-reviewed article...

PSTI : 0.59 (+3.51%)
Pluristem Files Patent Application for the Use of its Advanced Manufacturing Technology in the Cannabis Industry

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that it has filed a U.S. provisional...

PSTI : 0.59 (+3.51%)
Recent Analysis Shows OneMain, E*TRADE Financial, Keurig Dr Pepper, and Pluristem Therapeutics Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of OneMain Holdings, Inc. (NYSE:OMF),...

KDP : 30.83 (+1.31%)
OMF : 32.29 (+1.35%)
ETFC : 45.29 (+0.51%)
PSTI : 0.59 (+3.51%)
Pluristem Completes Interim Enrollment in Pivotal CLI Study, Targeting Potential Conditional Marketing Approval in Europe

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced the Company has achieved a significant...

PSTI : 0.59 (+3.51%)
Pluristem Therapeutics Issues Shareholder Update

-- Recent financing provides funding through multiple potentially value-creating milestones

PSTI : 0.59 (+3.51%)
Pluristem Therapeutics Inc. Announces Pricing of Its Public Offering and Registered Direct Offering for Aggregate Proceeds of Approximately $20 Million

Pluristem Therapeutics Inc. (Nasdaq: PSTI, TASE: PLTR) ("Pluristem" or "Company"), a leading regenerative medicine company developing novel placenta-based cell therapy product candidates, announced today...

PSTI : 0.59 (+3.51%)
Pluristem Therapeutics Inc. Announces Proposed Public Offering of Common Stock and Warrants and Concurrent Registered Direct Offering of Common Stock

Pluristem Therapeutics Inc. (Nasdaq: PSTI, TASE: PLTR) ("Pluristem" or "Company"), a leading regenerative medicine company developing novel placenta-based cell therapy product candidates, announced today...

PSTI : 0.59 (+3.51%)
Pluristem Therapeutics Announces Completion of 2nd Cohort and DSMB Approval to Enroll Final Cohort in Phase I Hematological Study of PLX-R18

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the Company has fully enrolled...

PSTI : 0.59 (+3.51%)
Pluristem Enters into Collaboration with NASA to Study PLX Therapeutic Benefits in Space Missions

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced a collaboration between the company...

PSTI : 0.59 (+3.51%)
Pluristem Therapeutics Sees Hammer Chart Pattern: Time to Buy?

Pluristem Therapeutics Inc. (PSTI) has been struggling lately, but the selling pressure may be coming to an end soon.

PSTI : 0.59 (+3.51%)
RESTORE Consortium, of which Pluristem is a member, Nominated to Be One of Two Finalists Competing for a Potential Award for Development of Advanced Therapeutics

-- RESTORE nominated as one of two Consortiums competing for an award up to EUR1 billion over the next 10 years by the European Commission (EC) for the development and advancement of transformative therapeutics...

PSTI : 0.59 (+3.51%)
Pluristem: Fiscal 2Q Earnings Snapshot

HAIFA, Israel (AP) _ Pluristem Therapeutics Inc. (PSTI) on Wednesday reported a loss of $8.7 million in its fiscal second quarter.

PSTI : 0.59 (+3.51%)
Pluristem to Collaborate with Israeli Ministry of Defense in the Treatment of Burn Injuries

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today reported the receipt of a joint grant awarded...

PSTI : 0.59 (+3.51%)

Van Meerten Stock Picks

Cohen & Steers REIT ETF
My Pick of the Day is the Cohen & Steers REIT ETF (ICF).
ICF +0.81
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar